Medications

Lomitapide in hypercholesterolaemia: No hint of added benefit

Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous familial hypercholesterolaemia in whom diet and other drugs do not sufficiently lower cholesterol levels. ...

Cardiology

Researchers identify a new approach for lowering harmful lipids

Xian-Cheng Jiang, PhD, professor of cell biology at SUNY Downstate Medical Center, has led a study identifying a new approach for lowering "bad" lipids in blood circulation, a critical means to combat devastating cardiovascular ...

Cardiology

Calculated LDL-C varies at lower values of measured LDL-C

(HealthDay)—At lower values of measured low-density lipoprotein cholesterol (LDL-C), the variation and bias of calculated LDL-C increases, according to a study published in the Aug. 15 issue of The American Journal of Cardiology.

Cardiology

Atorvastatin/Ezetimibe beats atorvastatin after PCI

(HealthDay)—For Japanese patients who have undergone percutaneous coronary intervention (PCI), atorvastatin plus ezetimibe is associated with improved outcomes versus atorvastatin alone, according to a study published in ...

Diabetes

Review explores effect of sulfonylureas on lipids in T2DM

(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), sulfonylureas seem to increase levels of free fatty acids (FFA) and triglycerides (TG) and lower low-density lipoprotein cholesterol (LDL-C) and high-density ...

Oncology & Cancer

Metabolic syndrome up with ADT in prostate cancer

(HealthDay)—For patients with prostate cancer treated with androgen deprivation therapy there are increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome, according to a study published ...

Diabetes

Changes observed in HbA1c during ramadan

(HealthDay)—For patients with type 2 diabetes, during Ramadan, the greatest change among metabolic parameters is seen for glycemia, according to a study published online May 13 in the Journal of Diabetes Investigation.

Cardiology

Glucose variation impacts coronary plaque vulnerability

(HealthDay)—For patients with coronary artery disease (CAD) pretreated with lipid-lowering therapy, daily glucose fluctuation may affect coronary plaque vulnerability, according to a study published in the May issue of ...

page 20 from 26